Boston Scientific announced it has received FDA approval for the Farapulse Pulsed Field Ablation, or PFA, System. The Farapulse PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation, or AF, and is a unique new alternative to standard-of-care thermal ablation treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific call volume above normal and directionally bullish
- BSX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Boston Scientific price target raised to $70 from $62 at Wells Fargo
- Boston Scientific price target raised to $72 from $62 at Piper Sandler
- Boston Scientific named 2024 Top Pick in MedTech at RBC Capital
